Addex Therapeutics raises $10 million in a Private Placement to International Institutional Investors
October 12, 2012 12:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 12 October 2012 - Addex...
Addex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 Meeting
October 11, 2012 01:50 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} ...
Addex and Collaborators Awarded Swiss CTI Grant to Develop Allosteric Modulators for Neurodegenerative and Psychiatric Diseases
October 02, 2012 01:05 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Grant to Further Characterize Allosteric Modulators...
Addex mGluR4 Allosteric Modulator Effective in Multiple Sclerosis Model - A Novel Oral Small Molecule Approach for the Treatment of Multiple Sclerosis
September 24, 2012 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 24 September 2012 - Addex...
Addex Partner Doses First Patient in Phase 2 Clinical Study of ADX71149 for the Treatment of Major Depressive Disorder Patients with Anxiety Symptoms
September 17, 2012 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 17 September 2012 - Addex...
Addex Therapeutics First Half 2012 Financial Results
August 22, 2012 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 22 August 2012 - Addex...
Addex Therapeutics First Half 2012 Financial Results Next Wednesday
August 20, 2012 01:28 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 20 August 2012 - Addex...
Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson's Disease Pre-Clinical Models
July 16, 2012 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Seminal Research Provides Greater Insight into the...
Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research
July 03, 2012 01:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 3 July 2012 - Addex...
Addex to Present Phase 2a Dipraglurant Data at Movement Disorder Society's International Congress
June 18, 2012 12:00 ET
|
Addex Therapeutics
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 18 June 2012 - Addex Therapeutics...